Stein J P, Skinner E C, Boyd S D, Skinner D G
Division of Urology, University of Southern California Medical School, Los Angeles.
J Urol. 1993 Mar;149(3):588-9. doi: 10.1016/s0022-5347(17)36156-6.
Cyclophosphamide has been used to treat a variety of malignant and nonmalignant diseases. The association of this agent with the development of urothelial tumors has been well documented. Although most bladder cancers associated with prior cyclophosphamide therapy are transitional cell carcinoma, to our knowledge there have been 6 reports of cyclophosphamide-induced squamous cell carcinoma of the bladder. We report 2 additional cases of squamous cell carcinoma of the bladder that occurred in patients after cyclophosphamide treatment for Wegener's granulomatosis. Any patient with a history of prolonged cyclophosphamide ingestion needs careful long-term monitoring of the lower urinary tract, since there is at least a 9-fold increase in the incidence of lower urinary tract malignancy in such patients.
环磷酰胺已被用于治疗多种恶性和非恶性疾病。该药物与尿路上皮肿瘤发生之间的关联已有充分记录。尽管大多数与既往环磷酰胺治疗相关的膀胱癌是移行细胞癌,但据我们所知,已有6例环磷酰胺诱发的膀胱鳞状细胞癌的报告。我们报告另外2例膀胱鳞状细胞癌病例,这2例发生在接受环磷酰胺治疗韦格纳肉芽肿病后的患者中。任何有长期摄入环磷酰胺病史的患者都需要对下尿路进行仔细的长期监测,因为这类患者下尿路恶性肿瘤的发病率至少增加9倍。